FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:333-335 July 28, 2005 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Interview Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

An infant in rural Africa has fever. Acetaminophen does not work. The fever spikes, and the father makes his way to the local kiosk and buys malaria medicine — chloroquine — that seems to help but then fails. A day later, the baby is dead.

The outcome has little to do with the curability of the disease and everything to do with economics — the economics of poverty and the economics of antimalarial drugs. It was this aspect of the malaria crisis that the U.S. Agency for International Development asked the Institute of Medicine to examine in 2001.¹

The Africa . . . [Full Text of this Article]

Source Information

Dr. Arrow is a professor emeritus of economics at Stanford University, Palo Alto, Calif. Ms. Gelband is senior program officer at the Institute of Medicine, Washington, D.C. Dr. Jamison is a professor of public health and of education at the University of California, Los Angeles.

An interview with Dr. Arrow can be heard at www.nejm.org.

This article has been cited by other articles:

• Scheindlin, S. (2005). Antimalarials: Shortages and Searches. Mol. Interv. 5: 268-272 [Full Text]